Avtor/Urednik     Böhm, Michael; Borer, Jeffrey S.; Camm, A. John; Ford, Ian; Lloyd, Suzanne M.; Komajda, Michel; Tavazzi, Luigi; Talajic, Mario; Lainščak, Mitja; Reil, Jan-Christian; Ukena, Christian; Swedberg, Karl
Naslov     Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy
Tip     članek
Vol. in št.     Letnik 17, št. 5
Leto izdaje     2015
Obseg     str. 518-526
ISSN     1388-9842 - European journal of heart failure
Jezik     eng
Abstrakt     Aims: Analysis of 24-h Holter recordings was a pre-specified substudy of SHIFT (Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial) for exploring the heart rhythm safety of ivabradine and to determine effects of ivabradine on 24-h, daytime, and night-time heart rate (HR) compared with resting office HR. Methods and results: The 24-h Holter monitoring was performed at baseline and 8 months after randomization to ivabradine (n = 298) or matching placebo (n = 304) titrated maximally to 7.5 mg b.i.d. in patients with baseline HR >-70 b.p.m. Patients received guideline-based optimized heart failure therapy including ACE inhibitors and/or ARBs in 93% and beta-blockers at maximally tolerated doses in 93%. After 8 months, HR over 24 h decreased by 9.5+-10.0 b.p.m. with ivabradine, from 75.4+-10.3 b.p.m. (P < 0.0001), and by 1.2+-8.9 b.p.m. with placebo, from 74.8+-9.7 b.p.m. (P < 0.0001 for difference vs. ivabradine). HR reduction with ivabradine was similar in resting office and in 24-h, awake, and asleep recordings, with beneficial effects on HR variability and no meaningful increases in supraventricular or ventricular arrhythmias. At 8 months, 21.3% on ivabradine vs. 8.5% on placebo had >-1 episode of HR <40 b.p.m. (P < 0.0001). No episode of HR <30 b.p.m. was recorded; 3 (1.2%) patients had RR intervals >2.5 s on ivabradine vs. 4 (1.6%) patients on placebo. No RR intervals >3 s were identified in patients taking ivabradine. Conclusion: Ivabradine safely and significantly lowers HR and improves HR variability in patients with systolic heart failure, without inducing significant bradycardia, ventricular arrhythmias, or supraventricular arrhythmias.
Deskriptorji     Heart failure
Heart rate
Electrocardiography, ambulatory
Cardiovascular agents
Srčno popuščanje
Srčni utrip
Elektrokardiografija, ambulamtna
Zdravila za srce in ožilje
Proste vsebinske oznake     ivabradine